EDITAS MEDICINE INC.

Editas Medicine Announces Third Quarter 2021 Results and Business Updates

08 نوفمبر 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and Cancer at the ASH Annual Meeting and Exposition

04 نوفمبر 2021 09:02:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Names Bernadette Connaughton to Board of Directors

28 أكتوبر 2021 09:00:02 بحسب Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update

25 أكتوبر 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Clinical Data from Editas Medicine’s Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene and Cell Therapy Annual Congress

20 أكتوبر 2021 09:00:01 بحسب Nasdaq GlobeNewswire

Editas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting

07 أكتوبر 2021 08:00:01 بحسب Nasdaq GlobeNewswire

Editas Medicine to Present at Chardan’s 5th Annual Genetic Medicines Conference

30 سبتمبر 2021 08:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10

29 سبتمبر 2021 09:00:01 بحسب Nasdaq GlobeNewswire

Editas Medicine Names Emma Reeve to Board of Directors

08 سبتمبر 2021 09:00:01 بحسب Nasdaq GlobeNewswire

Initial Clinical Data from Editas Medicine’s BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September

07 سبتمبر 2021 16:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine to Participate in Upcoming Investor Conferences

02 سبتمبر 2021 08:00:01 بحسب Nasdaq GlobeNewswire

Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers Meeting

20 أغسطس 2021 16:20:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces Second Quarter 2021 Results and Business Updates

04 أغسطس 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Editas Medicine and IDT Announce Publication in Nature Communications of Research Data Supporting the Use of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, in Researching the Potential of Gene-Edited Cell Medicines

29 يوليو 2021 09:00:01 بحسب Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing Second Quarter 2021 Results and Corporate Update

28 يوليو 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Editas Medicine Names Bruce E. Eaton, Ph.D., as Executive Vice President and Chief Business Officer

26 يوليو 2021 09:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Announces Enrollment of the First Pediatric Cohort in the BRILLIANCE Clinical Trial of EDIT-101 for the Treatment of LCA10 Following IDMC Endorsement

23 يونيو 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer

15 يونيو 2021 16:01:00 بحسب Nasdaq GlobeNewswire

Editas Medicine Strengthens Executive Leadership Team to Advance Pipeline and Support Long-term Growth

14 يونيو 2021 09:00:01 بحسب Nasdaq GlobeNewswire

Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress

11 يونيو 2021 06:00:00 بحسب Nasdaq GlobeNewswire